High-level production of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in high-density cultivation of recombinant Escherichia coli using a combined feeding strategy

被引:34
|
作者
Shen, YL [1 ]
Zhang, Y [1 ]
Sun, AY [1 ]
Xia, XX [1 ]
Wei, DZ [1 ]
Yang, SL [1 ]
机构
[1] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
combined feeding strategy; Escherichia coli; fed-batch; high-cell-density cultivation; TRAIL;
D O I
10.1023/B:BILE.0000030043.84226.ac
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recombinant Escherichia coli strain C600/pBV-TRAIL (encoding for 114-281 amino acids of TRAIL's soluble fragment) produced a recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL). Using a combined strategy of exponential feeding and pH-stat feeding, high concentrations of biomass (65 g dry wt l(-1)) and active soluble TRAIL (1.4 g l(-1)) were obtained within 30 h. The accumulation of acetate, which usually occurs during the process of high-density culture of Escherichia coli and especially in the induction stage of protein synthesis, was avoided.
引用
收藏
页码:981 / 984
页数:4
相关论文
共 8 条
  • [1] High-level production of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in high-density cultivation of recombinant Escherichia coli using a combined feeding strategy
    Ya-Ling Shen
    Yue Zhang
    Ai-You Sun
    Xiao-Xia Xia
    Dong-Zhi Wei
    Sheng-Li Yang
    Biotechnology Letters, 2004, 26 : 981 - 984
  • [2] Improvement of expression level and bioactivity of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) by a novel zinc ion feeding strategy
    Sun, Ai-You
    Shen, Ya-Ling
    Yin, Ji-Cheng
    Zhang, Hong
    Tang, Ya-Nan
    Wei, Dong-Zhi
    BIOTECHNOLOGY LETTERS, 2006, 28 (15) : 1215 - 1219
  • [3] Study of the crystal shape and its influence on the anti-tumor activity of tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL)
    Yin, Ji-Cheng
    Zhou, Jin-Song
    Suh, Jing
    Qiu, Yi
    Wei, Dong-Zhi
    Shen, Ya-Ling
    CRYSTAL RESEARCH AND TECHNOLOGY, 2008, 43 (08) : 888 - 893
  • [4] Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma
    Pasello, Giulia
    Urso, Loredana
    Silic-Benussi, Micol
    Schiavon, Marco
    Cavallari, Ilaria
    Marulli, Giuseppe
    Nannini, Nazarena
    Rea, Federico
    Ciminale, Vincenzo
    Favaretto, Adolfo
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (07) : 1008 - 1017
  • [5] Fed-batch production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in soluble form in Escherichia coli and its purification and characterization
    Li, Ping
    Gu, Qing
    Wu, Xuechang
    PROTEIN EXPRESSION AND PURIFICATION, 2016, 126 : 115 - 121
  • [6] Cytotoxic Effects of Camptothecin and Cisplatin Combined with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2L/TRAIL) in a Model of Primary Culture of Non-small Cell Lung Cancer
    Frese, Steffen
    Schueller, Alexandra
    Frese-Schaper, Manuela
    Gugger, Mathias
    Schmid, Ralph A.
    ANTICANCER RESEARCH, 2009, 29 (08) : 2905 - 2911
  • [7] Enhanced production of soluble tumor necrosis factor-related apoptosis-inducing ligand in Escherichia coli using a novel self-cleavable tag system Fh8-ΔI-CM
    Zhang, Min
    Wang, Zhanqing
    Chi, Lili
    Sun, Jing
    Shen, Yaling
    PROTEIN EXPRESSION AND PURIFICATION, 2018, 148 : 16 - 23
  • [8] Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
    Ouyang, Xuenong
    Shi, Meiqi
    Jie, Fangwei
    Bai, Yuxian
    Shen, Peng
    Yu, Zhuang
    Wang, Xiuwen
    Huang, Cheng
    Tao, Min
    Wang, Zhehai
    Xie, Conghua
    Wu, Qi
    Shu, Yongqian
    Han, Baohui
    Zhang, Fengchun
    Zhang, Yiping
    Hu, Chunhong
    Ma, Xitao
    Liang, Yongjie
    Wang, Anlan
    Lu, Bing
    Shi, Yi
    Chen, Jinfei
    Zhuang, Zhixiang
    Wang, Jiejun
    Huang, Jianjin
    Wang, Changhui
    Bai, Chunxue
    Zhou, Xin
    Li, Qiang
    Chen, Feng
    Yu, Hao
    Feng, Jifeng
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 315 - 322